Experimental study on inhibition of restenosis by osteopontin oligopeptide antagonist after de-endothelium.
- Author:
Jie LU
1
;
Mei HAN
;
Jin-kun WEN
;
Jing-jing LI
Author Information
- Publication Type:Journal Article
- MeSH: Animals; Cell Adhesion; drug effects; Cells, Cultured; Disease Models, Animal; Male; Muscle, Smooth, Vascular; cytology; drug effects; metabolism; Osteopontin; pharmacology; Rats; Rats, Sprague-Dawley; Tunica Intima; pathology
- From: Chinese Journal of Applied Physiology 2007;23(4):495-499
- CountryChina
- Language:Chinese
-
Abstract:
AIMOsteopontin 13-peptide(Gly158-Lys170), containing multi-function domains was used to inhibit the VSMC adhesion, migration. The mechanism of 13-peptide inhibiting neointima formation was investigated.
METHODSThe effect of 13-peptide on VSMC adhesion was tested by adhesion assay. The restenosis model was prepared balloon injury after administration of 13-peptide for 1 h, and then the 13-peptide was given by an intravenous drip for 7 days. The expression changes of OPN, FAK, ILK in vessel wall were detected by immunohistochemistry and Western blot.
RESULTSThe 13-peptide dose-dependently reduced adhesion of VSMC in OPN matrix, and the infiltration of macrophage in vessel wall also was reduced in the treatment group after balloon injury. The expression of OPN, FAK, ILK was down-regulated following with the inhibition of neointima thickening.
CONCLUSIONThe OPN 13-peptide can inhibit inflammation and neointima formation by blocking the binding of OPN to it's receptors.